OAC
SABS icon

OMERS Administration Corp’s SAB Biotherapeutics SABS Stock Holding History

OMERS Administration Corp’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,700
Closed -$114K – 1104
2026
Q1 		$114K Sell
29,700
-12,300
-29% -$49K ﹤0.01% 999
2025
Q4 		$157K Buy
+42,000
New +$138K ﹤0.01% 940

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OMERS Administration Corp's SABS Position: Q2 2026 in Review

OMERS Administration Corp sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 29,700 shares — an estimated $114K sold.

OMERS Administration Corp first reported a position in SABS in Q4 2025 and held it in 2 quarters. The position peaked at $157K in Q4 2025. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • OMERS Administration Corp reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 29,700 SAB Biotherapeutics shares in Q2 2026, an estimated $114K.
  • OMERS Administration Corp first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's SAB Biotherapeutics position peaked at $157K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.